×
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.69 (-0.68%)
MSFT   262.20 (-1.02%)
META   168.86 (-0.37%)
GOOGL   2,285.89 (-1.33%)
AMZN   110.75 (-2.18%)
TSLA   728.29 (-0.88%)
NVDA   164.98 (-2.20%)
NIO   22.27 (-2.96%)
BABA   120.19 (+1.23%)
AMD   82.76 (-3.95%)
MU   59.45 (+1.14%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.23 (+0.78%)
F   12.22 (+1.50%)
DIS   99.89 (+3.40%)
AMC   13.61 (-3.68%)
PFE   51.37 (-0.98%)
PYPL   75.20 (-0.97%)
NFLX   186.30 (-1.50%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.69 (-0.68%)
MSFT   262.20 (-1.02%)
META   168.86 (-0.37%)
GOOGL   2,285.89 (-1.33%)
AMZN   110.75 (-2.18%)
TSLA   728.29 (-0.88%)
NVDA   164.98 (-2.20%)
NIO   22.27 (-2.96%)
BABA   120.19 (+1.23%)
AMD   82.76 (-3.95%)
MU   59.45 (+1.14%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.23 (+0.78%)
F   12.22 (+1.50%)
DIS   99.89 (+3.40%)
AMC   13.61 (-3.68%)
PFE   51.37 (-0.98%)
PYPL   75.20 (-0.97%)
NFLX   186.30 (-1.50%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.69 (-0.68%)
MSFT   262.20 (-1.02%)
META   168.86 (-0.37%)
GOOGL   2,285.89 (-1.33%)
AMZN   110.75 (-2.18%)
TSLA   728.29 (-0.88%)
NVDA   164.98 (-2.20%)
NIO   22.27 (-2.96%)
BABA   120.19 (+1.23%)
AMD   82.76 (-3.95%)
MU   59.45 (+1.14%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.23 (+0.78%)
F   12.22 (+1.50%)
DIS   99.89 (+3.40%)
AMC   13.61 (-3.68%)
PFE   51.37 (-0.98%)
PYPL   75.20 (-0.97%)
NFLX   186.30 (-1.50%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.69 (-0.68%)
MSFT   262.20 (-1.02%)
META   168.86 (-0.37%)
GOOGL   2,285.89 (-1.33%)
AMZN   110.75 (-2.18%)
TSLA   728.29 (-0.88%)
NVDA   164.98 (-2.20%)
NIO   22.27 (-2.96%)
BABA   120.19 (+1.23%)
AMD   82.76 (-3.95%)
MU   59.45 (+1.14%)
CGC   3.71 (-2.11%)
T   20.95 (+0.82%)
GE   67.23 (+0.78%)
F   12.22 (+1.50%)
DIS   99.89 (+3.40%)
AMC   13.61 (-3.68%)
PFE   51.37 (-0.98%)
PYPL   75.20 (-0.97%)
NFLX   186.30 (-1.50%)
NASDAQ:BGNE

BeiGene Stock Forecast, Price & News

$163.73
-7.54 (-4.40%)
(As of 06/28/2022 10:52 AM ET)
Add
Compare
Today's Range
$163.02
$170.83
50-Day Range
$121.11
$177.99
52-Week Range
$118.18
$426.56
Volume
2,743 shs
Average Volume
308,080 shs
Market Capitalization
$16.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$315.33
30 days | 90 days | 365 days | Advanced Chart

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock Forecast (MarketRank)

Overall MarketRank

1.91 out of 5 stars

Medical Sector

679th out of 1,436 stocks

Pharmaceutical Preparations Industry

328th out of 687 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
BeiGene logo

About BeiGene (NASDAQ:BGNE)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

BGNE Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
8,200
Year Founded
2010

Company Calendar

Last Earnings
5/05/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$315.33
High Stock Price Forecast
$431.00
Low Stock Price Forecast
$177.00
Forecasted Upside/Downside
+92.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$-1.41 billion
Net Margins
-218.25%
Pretax Margin
-219.11%

Debt

Sales & Book Value

Annual Sales
$1.18 billion
Book Value
$60.95 per share

Miscellaneous

Free Float
94,085,000
Market Cap
$16.91 billion
Optionable
Optionable
Beta
0.87

Social Links















BeiGene Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BeiGene stock.
View analyst ratings for BeiGene
or view top-rated stocks.

What is BeiGene's stock price forecast for 2022?

6 Wall Street research analysts have issued 12-month price objectives for BeiGene's shares. Their BGNE stock forecasts range from $177.00 to $431.00. On average, they anticipate BeiGene's stock price to reach $315.33 in the next year. This suggests a possible upside of 91.2% from the stock's current price.
View analysts' price targets for BeiGene
or view top-rated stocks among Wall Street analysts.

How has BeiGene's stock price performed in 2022?

BeiGene's stock was trading at $270.93 at the beginning of 2022. Since then, BGNE shares have decreased by 39.1% and is now trading at $164.91.
View the best growth stocks for 2022 here
.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for BeiGene
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) announced its quarterly earnings results on Thursday, May, 5th. The company reported ($4.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.52) by $0.28. The business earned $306.60 million during the quarter, compared to analyst estimates of $300.41 million. BeiGene had a negative trailing twelve-month return on equity of 40.10% and a negative net margin of 218.25%. The firm's revenue for the quarter was down 49.4% on a year-over-year basis.
View BeiGene's earnings history
.

Who are BeiGene's key executives?

BeiGene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, Exec. Chairman & CEO (Age 54, Pay $1.75M) (LinkedIn Profile)
  • Dr. Xiaobin Wu Ph.D., Pres, COO & GM of China (Age 60, Pay $1.64M)
  • Dr. Xiaodong Wang Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director (Age 59, Pay $250k)
  • Ms. Julia Wang, CFO & Principal Accounting Officer (Age 51, Pay $798.14k)
  • Mr. Wang Lai, Global Head of R&D (Age 45, Pay $1.13M)
  • Dr. Edna Huang M.D., Consultant (Age 49, Pay $768.08k)
  • Mr. Daniel Maller, VP of Fin. & Accounting
  • Ms. Mi Zhou, Sr. Director of Investor Relations
  • Mr. Kevin C. Mannix, Sr. VP of Investor Relations.
  • Mr. Scott Samuels, Sr. VP & Gen. Counsel

What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by many different retail and institutional investors. Top institutional investors include Capital International Investors (6.84%), Baillie Gifford & Co. (4.00%), Primecap Management Co. CA (3.61%), Temasek Holdings Private Ltd (2.88%), Invesco Ltd. (2.65%) and BlackRock Inc. (2.63%). Company insiders that own BeiGene stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene
.

Which institutional investors are selling BeiGene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Invesco Ltd., Fiera Capital Corp, USS Investment Management Ltd, State Street Corp, Matthews International Capital Management LLC, New York State Common Retirement Fund, and Baillie Gifford & Co.. Company insiders that have sold BeiGene company stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for BeiGene
or view top insider-selling stocks.

Which institutional investors are buying BeiGene stock?

BGNE stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Bank of America Corp DE, Bridgewater Associates LP, Zeal Asset Management Ltd, Capital Group International Inc. CA , Capital Group Private Client Services Inc., BlackRock Inc., and Goldman Sachs Group Inc.. Company insiders that have bought BeiGene stock in the last two years include Amgen Inc, and Ltd Beigene.
View insider buying and selling activity for BeiGene
or or view top insider-buying stocks.

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $164.91.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $17.03 billion and generates $1.18 billion in revenue each year. The company earns $-1.41 billion in net income (profit) each year or ($20.090010) on an earnings per share basis.

How many employees does BeiGene have?

BeiGene employs 8,200 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for BeiGene is www.beigene.com. The company can be reached via phone at 861085148500 or via email at [email protected].

This page (NASDAQ:BGNE) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.